CSTL
NASD Castle Biosciences, Inc.$36.65 ↑ +0.00 (+0.00%) Trading Up from the previous close of $36.65, $0.11 below the day’s high of $36.76
- YTD change
- -5.78%
- vs 20-day SMA
- +5.92%
- vs 200-day SMA
- +26.00%
Price ranges
Price & Performance
+10.83 (+43.79%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 66.0% away from all-time highs of $107.69
- CSTL is down 6% since the beginning of the year
- CSTL is up 61% over the past 12 months
- CSTL is up 12% over the past 1 month
- 6% of all CSTL investors are betting against CSTL
CSTL reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +52.6%.
- Previous minute
- +$0.00
- Last hour
- +$2.19
- Last 5 days
- +2.35%
- vs 8-day SMA
- +3.59%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
